CAMP4 Therapeutics Corporation (CAMP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Ind ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

PresentationCourtney BreenSanford C. Bernstein & Co., LLC., Research Division Fantastic. Hi, everyone. It's great to have you here today. Thank you so much for joining us. I am privileged to be sharing the stage with Rose Loughlin here from Moderna. For those of you who do not know me, my name is Courtney Breen. I cover the U.S. large cap names here at Bernstein. And we're hoping to have a bit of a conversation, particularly into the oncology portfolio at Moderna today. We're going to start first, though, ...

Key Takeaways RIGL's Tavalisse drove $68.5M sales in H1 2025, up 44% year over year, driving top-line growth.RIGL raised its 2025 revenue outlook to $270-$280M on strong performance across its marketed products.FOLD's Galafold posted $233.1M H1 2025 sales, up 11% year over year, with patent protection to 2038.Both Rigel Pharmaceuticals (RIGL) and Amicus Therapeutics (FOLD) are developing and commercializing treatments for rare medical conditions where existing therapies are limited, with the goal of establi ...

Key Takeaways QURE stock soared 247.7% after AMT-130 met primary and secondary endpoints in Huntington's disease study.High-dose AMT-130 slowed disease progression by 75% on cUHDRS and 60% on TFC at 36 months.AMT-130 showed dose-dependent benefits on motor and cognitive function with a manageable safety profile.Shares of uniQure N.V. (QURE) skyrocketed 247.7% on Wednesday after the company reported meeting key goals in the pivotal early to mid-stage study of its investigational gene therapy, AMT-130, for th ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Jasp ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) - ...

**公司及行业** * 公司为Moderna 专注于利用mRNA平台开发肿瘤治疗产品[1][5][27] * 行业涉及肿瘤免疫治疗 包括个体化新抗原疗法、现成癌症抗原疗法、T细胞衔接器、细胞疗法增强剂和体内细胞疗法[5][11][17][21] **核心观点与论据** * **个体化新抗原疗法(INT/mRNA-4157)临床效益显著** 在辅助黑色素瘤III期研究中与Keytruda联用可将患者癌症复发或死亡风险降低49% 远处转移风险降低62%[6][7] * **安全性表现突出** 所有肿瘤抗原疗法均显示良好耐受性 与Keytruda联用未出现额外安全性问题[7][14] * **现成癌症抗原疗法采用"即用型"设计** mRNA-4359靶向PD-L1和IDO蛋白 适用于多种癌症类型 预计2024年10月ESMO公布与Keytruda联用的ARM1B数据[11][12][13] * **T细胞衔接器平台具有多重靶向优势** 可同时靶向三个表面抗原(mRNA-2808) 并通过mRNA平台提供共刺激信号 增强T细胞活性和特异性[18][19] * **细胞疗法增强剂可改善实体瘤疗效** mRNA-4203设计用于增强Immatics的体外TCRT疗法(IMA203) 通过编码相同抗原来提升工程化T细胞反应[21][23][24] **其他重要内容** * **关键研发里程碑明确** 2026年将公布INT五年随访数据和III期辅助黑色素瘤研究结果 2024年10月ESMO公布mRNA-4359的ARM1B数据[6][9][13][39] * **开发策略系统化** 从高肿瘤突变负荷(黑色素瘤)到低突变负荷癌症 从早期辅助设置到晚期转移设置进行方法学探索[43][44] * **合作伙伴关系策略多样** 与默克(Merck)就INT项目达成50/50成本与利润共享合作 与Immatics合作开发T细胞衔接器靶向细胞内抗原[60] * **平台技术优势明显** mRNA平台可实现多重靶向(最多三个抗原) 并能够编码共刺激蛋白 相比重组蛋白方法具有差异化优势[18][19] * **竞争格局存在差异** BioNTech的iNEST使用20个新抗原和静脉输注脂质复合物 IO Biotech的肽疫苗虽错过统计学显著性但验证了PD-L1/IDO靶点的生物学假设[51][52][53]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...